Home › NDC Lookup › RxCUI directory › RxCUI 1870964

Deflazacort 22.75 MG/ML Oral Suspension — RxCUI 1870964

RxNorm drug concept · Semantic clinical drug
RxCUI 1870964 Semantic clinical drug · SCD ● Current RxNorm concept 12 FDA products 12 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1870964
Official nameDeflazacort 22.75 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped12
Package NDCs mapped12
Reported Medicaid activity (SDUD)11,524 prescriptions · 30 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Deflazacort: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Deflazacort is used to treat Duchenne muscular dystrophy (DMD), a genetic disease that causes muscles to weaken and break down over time. It's a corticosteroid — a type of anti-inf...
  • Yes — several brands, including Emflaza, Jaythari, and Kymbee tablets, can be crushed and mixed immediately with applesauce if swallowing a whole tablet is difficult. The oral susp...
  • Can my child take the tablet if they have trouble swallowing pills?
  • Many children on deflazacort develop a rounder, puffier face (sometimes called a 'moon face'), gain weight, grow more body hair, and get more frequent infections — these are common...
📖 Read our full Deflazacort guide →

🕸️ Concept Web — How Deflazacort 22.75 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Deflazacort 22.75 MG/ML Oral Suspension RxCUI 1870964

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Deflazacort 22396
  2. Brand names 4

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Emflaza 1870945
    • Jaythari 2716699
    • Kymbee 2725486
    • Pyquvi 2719193
  3. Dose forms 18

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Deflazacort Oral Suspension 1870963
    • Deflazacort Oral Liquid Product 1870962
    • Deflazacort Oral Product 1157200
    • Deflazacort Oral Suspension [Emflaza] 1870966
    • Deflazacort Oral Suspension [Jaythari] 2727380
    • Deflazacort Oral Suspension [Kymbee] 2745409
    • Deflazacort Oral Suspension [Pyquvi] 2719197
    • Emflaza Oral Liquid Product 1870967
    • +10 more in this family
  4. Clinical & branded drugs 9

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 21 of 32 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Deflazacort 22.75 MG/ML SCDC · 1870961
  • Deflazacort Oral Suspension SCDF · 1870963
  • Deflazacort Oral Liquid Product SCDG · 1870962
  • Deflazacort Oral Product SCDG · 1157200

Brand-Name Concepts

📦 FDA Products & Package NDCs

12 products · 12 package NDCs
12 package NDCs map to RxCUI 1870964 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00245-0813-13 1 BOTTLE in 1 CARTON (0245-0813-13) / 13 mL in 1 BOTTLE KYMBEE Upsher-Smith Laboratories, LLC 2026-06-05
27808-0249-01 13 mL in 1 BOTTLE (27808-249-01) Deflazacort Oral Suspension Cranbury Pharmaceuticals, LLC 2024-05-01
52856-0501-01 100 TABLET in 1 BOTTLE (52856-501-01) EMFLAZA PTC Therapeutics, Inc. 2018-09-10
52856-0502-03 30 TABLET in 1 BOTTLE (52856-502-03) EMFLAZA PTC Therapeutics, Inc. 2018-09-10
52856-0503-03 30 TABLET in 1 BOTTLE (52856-503-03) EMFLAZA PTC Therapeutics, Inc. 2018-09-10
52856-0504-03 30 TABLET in 1 BOTTLE (52856-504-03) EMFLAZA PTC Therapeutics, Inc. 2018-09-10
52856-0505-22 13 mL in 1 BOTTLE (52856-505-22) EMFLAZA PTC Therapeutics, Inc. 2019-08-30
57664-0993-01 13 mL in 1 BOTTLE (57664-993-01) Deflazacort Oral Suspension Sun Pharmaceutical Industries, Inc. 2026-02-02
70710-2007-03 1 BOTTLE in 1 CARTON (70710-2007-3) / 13 mL in 1 BOTTLE Deflazacort Oral Suspension Zydus Pharmaceuticals (USA) Inc. 2025-10-23
70710-2131-03 1 BOTTLE in 1 CARTON (70710-2131-3) / 13 mL in 1 BOTTLE JAYTHARI Oral Suspension Zydus Pharmaceuticals (USA) Inc. 2025-11-20
73289-0089-01 13 mL in 1 BOTTLE (73289-0089-1) PYQUVI Aucta Pharmaceuticals, Inc. 2025-06-30
81806-0200-73 1 BOTTLE in 1 CARTON (81806-200-73) / 13 mL in 1 BOTTLE Deflazacort Oral Suspension Doppel Farmaceutici S.r.l. 2025-10-23
Observed labelers: PTC Therapeutics, Inc. (5) · Zydus Pharmaceuticals (USA) Inc. (2) · Aucta Pharmaceuticals, Inc. (1) · Cranbury Pharmaceuticals, LLC (1) · Doppel Farmaceutici S.r.l. (1) · Sun Pharmaceutical Industries, Inc. (1) · +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.